P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer

References

• Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009;625:41–54.
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432–1433.
   PubMed Web of Science ®Google Scholar
• Wei Y. The influence of calcium infiltration on the sintering behavior and dissolution of beta-tricalcium phosphate [Master thesis]. University of Pittsburgh; 2015.
   Google Scholar
• Jaffee EM. Immunotherapy of cancer. Ann N Y Acad Sci. 1999;886:67–72.
   PubMed Web of Science ®Google Scholar
• Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 2000;13:265–276.
   PubMed Web of Science ®Google Scholar
• Matsui K, O’Mara LA, Allen PM. Successful elimination of large established tumors and avoidance of antigen‐loss variants by aggressive adoptive T cell immunotherapy. Int Immunol. 2003;15:797–805.
   PubMed Web of Science ®Google Scholar
• Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357:1777–1789.
   PubMed Web of Science ®Google Scholar
• Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol. 2008;20:89–95.
   PubMed Web of Science ®Google Scholar
• Babai I, Barenholz Y, Zakay-Rones Z, et al. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin–neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. Vaccine. 2001;20:505–515.
   PubMed Web of Science ®Google Scholar
• Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta. 2002;1589:1–13.
   PubMed Web of Science ®Google Scholar
• Krieg A, Davis H. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Therap. 2001;3:15–24.
   PubMedGoogle Scholar
• Amir Jalali S, Parmiani G. Pre-clinical and clinical aspects of peptide-based vaccine against human solid tumors. Recent Pat Biotechnol. 2011;5:108–117.
   PubMedGoogle Scholar
• Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine. 2012;30:2256–2272.
   PubMed Web of Science ®Google Scholar
• Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods. 1991;140:1–13.
   PubMed Web of Science ®Google Scholar
• Zamani P, Momtazi-Borojeni AA, Nik ME, et al. Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy. J Cell Physiol. 2018;233:5189–5199.
   PubMed Web of Science ®Google Scholar
• Nordly P, Madsen HB, Nielsen HM, et al. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Exp Opin Drug Deliv. 2009;6:657–672.
   PubMed Web of Science ®Google Scholar
• Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotechnol. 1995;6:495–524.
   Google Scholar
• Alving CR. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. Immunobiology. 1993;187:430–446.
   PubMed Web of Science ®Google Scholar
• Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol Life Sci. 2008;65:3231.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1:894–907.
   PubMed Web of Science ®Google Scholar
• Brubaker SW, Bonham KS, Zanoni I, et al. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol. 2015;33:257–290.
   PubMed Web of Science ®Google Scholar
• Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001;61:1–13.
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Sotiriadou NN, Gritzapis AD, et al. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother. 2006;55:85–95.
   PubMed Web of Science ®Google Scholar
• Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 1994;54:16–20.
   PubMed Web of Science ®Google Scholar
• Shariat S, Badiee A, Jalali SA, et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. 2014;355:54–60.
   PubMed Web of Science ®Google Scholar
• Mansourian M, Badiee A, Jalali SA, et al. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol Lett. 2014;162:87–93.
   PubMed Web of Science ®Google Scholar
• Yazdani M, Amir Jalali S, Badiee A, et al. Stimulation of tumor-specific immunity by p5 HER-2/neu generated peptide encapsulated in nano-liposomes with high phase transition temperature phospholipids. Curr Drug Deliv. 2017;14:492–502.
   PubMed Web of Science ®Google Scholar
• Talesh GA, Ebrahimi Z, Badiee A, et al. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunol Lett. 2016;176:57–64.
   PubMed Web of Science ®Google Scholar
• Jalali SA, Sankian M, Tavakkol-Afshari J, et al. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomed Nanotechnol Biol Med. 2012;8:692–701.
   PubMed Web of Science ®Google Scholar
• Banchereau JSRM. Dendritic cells and the control of immunity. Nature. 1998;395:245–252.
   Web of Science ®Google Scholar
• Banchereau JBF, Caux C, Davoust J, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.
   PubMed Web of Science ®Google Scholar
• Moghimi SMHAE, Christy NM, Gray T, et al. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett. 1994;344:25–30.
   PubMed Web of Science ®Google Scholar
• Hawley AE, Illum L, Davis SS. Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm Res. 1997;14:657–661.
   PubMed Web of Science ®Google Scholar
• Illum LCAE, Butterworth MD, Arien A, et al. Development of systems for targeting the regional lymph nodes for diagnostic imaging: in vivo behaviour of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration. Pharm Res. 2001;18:640–645.
   PubMed Web of Science ®Google Scholar
• MS M. The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials. 2006;27:136–144.
   PubMed Web of Science ®Google Scholar
• Zhan X, Tran KK, Shen H. Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration. Mol Pharm. 2012;9:3442–3451.
   PubMed Web of Science ®Google Scholar
• Eiji Y. Design of pH-sensitive polymer-modified liposomes for antigen delivery and their application in cancer immunotherapy. Polym J. 2016;48:761–771.
   Web of Science ®Google Scholar
• Bungener LSK, Bijl L, Leserman L, et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine. 2002;20:2287–2295.
   PubMed Web of Science ®Google Scholar
• Bungener LHA, de Mare A, de Vries-Idema J, et al. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine. 2005;23:1232–1241.
   PubMed Web of Science ®Google Scholar
• Shariat S, Badiee A, Jaafari MR, et al. Optimization of a method to prepare liposomes containing HER2/Neu-derived peptide as a vaccine delivery system for breast cancer. Iran J Pharm Res. 2014;13:15–25.
   PubMed Web of Science ®Google Scholar
• Schagger H. Tricine-SDS-PAGE. Nat Protoc. 2006;1(1):16–22.
   PubMed Web of Science ®Google Scholar
• Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–468.
   PubMed Web of Science ®Google Scholar
• Harmon P, Cabral-Lilly D, Reed RA, et al. The release and detection of endotoxin from liposomes. Anal Biochem. 1997;250:139–146.
   PubMed Web of Science ®Google Scholar
• Nikpoor AR, Tavakkol-Afshari J, Sadri K, et al. Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: in vitro and in vivo studies. Nanomed Nanotechnol Biol Med. 2017;13:2671–2682.
   PubMed Web of Science ®Google Scholar
• Lichtenfels R, Biddison WE, Schulz H, et al. CARE-LASS (calcein-release-assay), an improved fluorescence-based test system to measure cytotoxic T lymphocyte activity. J Immunol Methods. 1994;172:227–239.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Bonifaz L, Fujii SI, et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol. 2005;560:83–97.
   PubMed Web of Science ®Google Scholar
• Reddy R, Zhou F, Huang L, et al. pH sensitive liposomes provide an efficient means of sensitizing target cells to class I restricted CTL recognition of a soluble protein. J Immunol Methods. 1991;141:157–163.
   PubMed Web of Science ®Google Scholar
• Matyas GR, Mayorov AV, Rice KC, et al. Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine. 2013;31:2804–2810.
   PubMed Web of Science ®Google Scholar
• Ghaffari-Nazari H, Tavakkol-Afshari J, Jaafari MR, et al. Improving multi-epitope long peptide vaccine potency by using a strategy that enhances CD4+ T help in BALB/c mice. PLoS One. 2015;10:e0142563.
   PubMed Web of Science ®Google Scholar
• Hale AH. H-2 antigens incorporated into phospholipid vesicles elicit specific allogeneic cytotoxic T lymphocytes. Cell Immunol. 1980;55:328–341.
   PubMed Web of Science ®Google Scholar
• Raphael L, Tom B. Liposome facilitated xenogeneic approach for studying human colon cancer immunity: carrier and adjuvant effect of liposomes. Clin Exp Immunol. 1984;55:1.
   PubMed Web of Science ®Google Scholar
• Firouzmand H, Badiee A, Khamesipour A, et al. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Tropica. 2013;128:528–535.
   PubMed Web of Science ®Google Scholar
• Barati N, Nikpoor AR, Razazan A, et al. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Immunol Lett. 2017;190:108–117.
   PubMed Web of Science ®Google Scholar
• Nair S, Zhou F, Reddy R, et al. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med. 1992;175:609–612.
   PubMed Web of Science ®Google Scholar
• Chang J-S, Choi M-J, Cheong H-S, et al. Development of Th1-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine. 2001;19:3608–3614.
   PubMed Web of Science ®Google Scholar
• Luo L, Li Y, Chang J-S, et al. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120. Virology. 1998;240:316–325.
   PubMed Web of Science ®Google Scholar
• Siegel D, Epand R. The mechanism of lamellar-to-inverted hexagonal phase transitions in phosphatidylethanolamine: implications for membrane fusion mechanisms. Biophys J. 1997;73:3089–3111.
   PubMed Web of Science ®Google Scholar
• Connor J, Yatvin MB, Huang L. pH-sensitive liposomes: acid-induced liposome fusion. Proc Natl Acad Sci. 1984;81:1715–1718.
   PubMed Web of Science ®Google Scholar
• Düzgüneş N, Straubinger RM, Baldwin PA, et al. Proton-induced fusion of oleic acid-phosphatidylethanolamine liposomes. Biochemistry. 1985;24:3091–3098.
   PubMed Web of Science ®Google Scholar
• Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8:934–943.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10:787.
   PubMed Web of Science ®Google Scholar
• Badiee A, Khamesipour A, Samiei A, et al. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Exp Parasitol. 2012;132:403–409.
   PubMed Web of Science ®Google Scholar